The latest price target for 4D Molecular Therapeutics (NASDAQ:FDMT) was reported by B. Riley Securities on July 31, 2026. The analyst firm set a price target for $37.00 expecting FDMT to rise to within 12 months (a possible 143.42% upside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for 4D Molecular Therapeutics (NASDAQ:FDMT) was provided by B. Riley Securities, and 4D Molecular Therapeutics initiated their buy rating.

There is no last upgrade for 4D Molecular Therapeutics

The last downgrade for 4D Molecular Therapeutics Inc happened on September 23, 2024 when Cantor Fitzgerald changed their price target from N/A to N/A for 4D Molecular Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 4D Molecular Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 4D Molecular Therapeutics was filed on July 31, 2026 so you should expect the next rating to be made available sometime around July 31, 2027.

While ratings are subjective and will change, the latest 4D Molecular Therapeutics (FDMT) rating was a initiated with a price target of $0.00 to $37.00. The current price 4D Molecular Therapeutics (FDMT) is trading at is $15.20, which is within the analyst’s predicted range.